

CITATION REPORT

List of articles citing

H_yx law: predicting serious hepatotoxicity

DOI: 10.1002/pds.1211

Pharmacoepidemiology and Drug Safety, 2006, 15, 241-3.

Source: <https://exaly.com/paper-pdf/40322049/citation-report.pdf>

Version: 2024-04-26

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
269	The use of hepatotoxic signals to predict the safety of peroxisome proliferator-activated receptor agonists. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2006 , 2, 489-92	5.5	1
268	Current awareness: Pharmacoepidemiology and drug safety. <i>Pharmacoepidemiology and Drug Safety</i> , 2006 , 15, i-xii	2.6	
267	Retrospective analysis of transient elevations in alanine aminotransferase during long-term treatment with acetaminophen in osteoarthritis clinical trials. 2006 , 22, 2137-48		48
266	Drug-induced liver disease in 2006. 2007 , 23, 244-54		28
265	Monitoring liver safety in drug development: the GSK experience. 2007 , 49, 90-100		18
264	Incidence and prevalence of abnormal liver associated enzymes in patients with atrial fibrillation in a routine clinical care population. <i>Pharmacoepidemiology and Drug Safety</i> , 2008 , 17, 43-51	2.6	16
263	Background incidence of liver chemistry abnormalities in a clinical trial population without underlying liver disease. 2008 , 52, 85-8		20
262	Metabolism and related human risk factors for hepatic damage by usnic acid containing nutritional supplements. 2008 , 38, 264-80		32
261	Effects of succinobucol (AGI-1067) after an acute coronary syndrome: a randomised, double-blind, placebo-controlled trial. 2008 , 371, 1761-8		149
260	Cellular imaging predictions of clinical drug-induced liver injury. 2008 , 105, 97-105		394
259	Detecting outliers in multivariate laboratory data. 2008 , 18, 1178-83		8
258	Complexities in drug trials: enrichment, biomarkers and surrogates. Interview with Robert Temple. 2008 , 2, 109-12		4
257	Toxic and Drug-Induced Disorders of the Liver. 2009 , 1059-1086		1
256	The future of drug safety testing: expanding the view and narrowing the focus. 2009 , 14, 162-7		213
255	Imaging of deep venous thrombosis in patients using a radiolabelled anti-D-dimer Fab' fragment (99mTc-DI-DD3B6/22-80B3): results of a phase I trial. 2009 , 36, 250-9		18
254	Liver safety in patients with type 2 diabetes treated with pioglitazone: results from a 3-year, randomized, comparator-controlled study in the US. <i>Drug Safety</i> , 2009 , 32, 787-800	5.1	35
253	Tissue-specific, non-invasive toxicity biomarkers: translation from preclinical safety assessment to clinical safety monitoring. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2009 , 5, 1023-38	5.5	47

252	Drug-induced liver injury: what was new in 2008?. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2009 , 5, 843-60	5.5	46
251	Evidence-Based Liver Chemistry Monitoring in Drug Development. 2009 , 23, 149-158		3
250	Hepatic safety and tolerability in the maraviroc clinical development program. 2010 , 24, 2743-50		18
249	Impact of biomarker development on drug safety assessment. 2010 , 243, 167-79		66
248	Enhancing the utility of alanine aminotransferase as a reference standard biomarker for drug-induced liver injury. 2010 , 56, 237-46		58
247	Acetaminophen dosing of humans results in blood transcriptome and metabolome changes consistent with impaired oxidative phosphorylation. <i>Hepatology</i> , 2010 , 51, 227-36	11.2	71
246	Standardization of nomenclature and causality assessment in drug-induced liver injury: summary of a clinical research workshop. <i>Hepatology</i> , 2010 , 52, 730-42	11.2	206
245	A genome-wide study identifies HLA alleles associated with lumiracoxib-related liver injury. 2010 , 42, 711-4		325
244	Unintended hepatic adverse events associated with cancer chemotherapy. 2010 , 38, 142-7		17
243	Trabectedin plus pegylated liposomal Doxorubicin in recurrent ovarian cancer. 2010 , 28, 3107-14		317
242	CCR5 antagonists: host-targeted antiviral agents for the treatment of HIV infection, 4 years on. 2010 , 20, 179-92		27
241	Hepatic Toxicity. 2010 , 353-377		
240	Single-center experience with drug-induced liver injury from India: causes, outcome, prognosis, and predictors of mortality. <i>American Journal of Gastroenterology</i> , 2010 , 105, 2396-404	0.7	147
239	Mechanisms of drug-induced liver injury: from bedside to bench. 2011 , 8, 202-11		187
238	Recurrent drug-induced liver injury (DILI) with different drugs in the Spanish Registry: the dilemma of the relationship to autoimmune hepatitis. <i>Journal of Hepatology</i> , 2011 , 55, 820-7	13.4	68
237	Hepatobiliary laboratory abnormalities among patients with chronic or persistent immune thrombocytopenia (ITP). 2011 , 10, 188-195		3
236	FDA-approved drug labeling for the study of drug-induced liver injury. 2011 , 16, 697-703		268
235	Drug-induced autoimmune-like hepatitis. 2011 , 56, 958-76		178

234	Continuous reporting of new cases in Spain supports the relationship between Herbalife® products and liver injury. <i>Pharmacoepidemiology and Drug Safety</i> , 2011 , 20, 1080-7	2.6	30
233	Controlling autophagy: a new concept for clearing liver disease. <i>Hepatology</i> , 2011 , 53, 356-8	11.2	11
232	Identifying who is at risk of drug-induced liver injury: is human leukocyte antigen specificity the key?. <i>Hepatology</i> , 2011 , 53, 358-62	11.2	7
231	The genetics of primary biliary cirrhosis: the revolution moves on. <i>Hepatology</i> , 2011 , 53, 362-4	11.2	3
230	Laboratory Tests in Liver Disease. 2011 , 55-62		1
229	Lapaquistat acetate: development of a squalene synthase inhibitor for the treatment of hypercholesterolemia. 2011 , 123, 1974-85		47
228	Truncated robust distance for clinical laboratory safety data monitoring and assessment. 2012 , 22, 1174-92		5
227	Probable dalteparin-induced hepatotoxicity in a man with alpha-1-antitrypsin deficiency. 2012 , 52, 1764-7		3
226	Safety and Pharmacokinetics of Nelfinavir During the Second and Third Trimesters of Pregnancy and Postpartum. 2012 , 13, 46-59		9
225	Validation of multivariate outlier detection analyses used to identify potential drug-induced liver injury in clinical trial populations. <i>Drug Safety</i> , 2012 , 35, 865-75	5.1	11
224	Current challenges and controversies in drug-induced liver injury. <i>Drug Safety</i> , 2012 , 35, 1099-117	5.1	52
223	Drug-mediated toxicity: illuminating the 'bad' in the test tube by means of cellular assays?. 2012 , 33, 353-64		16
222	Comparisons between in vitro whole cell imaging and in vivo zebrafish-based approaches for identifying potential human hepatotoxicants earlier in pharmaceutical development. 2012 , 44, 127-40		79
221	Long-term hepatic safety of ambrisentan in patients with pulmonary arterial hypertension. 2012 , 60, 80-1		34
220	An Update on Drug-induced Liver Injury. <i>Journal of Clinical and Experimental Hepatology</i> , 2012 , 2, 247-59	4.1	79
219	Answers to multiple choice questions. <i>Journal of Clinical and Experimental Hepatology</i> , 2012 , 2, 401-6	4.1	
218	Placebo-controlled trial of oral laquinimod for multiple sclerosis. <i>New England Journal of Medicine</i> , 2012 , 366, 1000-9	59.2	290
217	A phase I and pharmacokinetic study of elisidepsin (PM02734) in patients with advanced solid tumors. 2012 , 70, 673-81		18

216	Drug-induced liver injury: present and future. <i>Clinical and Molecular Hepatology</i> , 2012 , 18, 249-57	6.9	92
215	Pretreatment data is highly predictive of liver chemistry signals in clinical trials. 2012 , 6, 359-69		2
214	A randomized, placebo- and active-controlled, parallel-group, multicentre, investigator-blinded study of four treatment regimens of posaconazole in adults with toenail onychomycosis. 2012 , 166, 389-98		44
213	Background incidence of liver chemistry abnormalities in pediatric clinical trials for conditions with and without underlying liver disease. 2012 , 62, 329-35		6
212	Clinical manifestations and treatment of drug-induced hepatotoxicity. 2013 , 17, 565-73, viii		11
211	Nonsteroidal anti-inflammatory drug-induced hepatotoxicity. 2013 , 17, 643-56, ix		35
210	Perturbation of bile acid homeostasis is an early pathogenesis event of drug induced liver injury in rats. 2013 , 268, 79-89		80
209	Drug-Induced Liver Injury Throughout the Drug Development Life Cycle: Where We Have Been, Where We are Now, and Where We are Headed. Perspectives of a Clinical Hepatologist. 2013 , 27, 165-191		14
208	Development of blood biomarkers for drug-induced liver injury: an evaluation of their potential for risk assessment and diagnostics. 2013 , 17, 343-54		36
207	Oral BG-12 (dimethyl fumarate) for relapsing-remitting multiple sclerosis: a review of DEFINE and CONFIRM. Evaluation of: Gold R, Kappos L, Arnold D, et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. <i>N Engl J Med</i> 2012;367:1098-107; and Fox RJ, Miller DH, Phillips JT, et al. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis.		28
206	Why the threshold criteria should not be modified for detection of possibly serious drug-induced hepatotoxicity in special groups of trial subjects. <i>Pharmacoepidemiology and Drug Safety</i> , 2013 , 22, 579-82 ⁶		4
205	How to avoid being surprised by hepatotoxicity at the final stages of drug development and approval. 2013 , 17, 749-67, xi		17
204	Trabectedin as single agent in the salvage treatment of heavily treated ovarian cancer patients: a retrospective, multicenter study. 2013 , 130, 505-10		18
203	Low-density lipoprotein lowering in 2013 by nonstatin agents: the discovery and development of promising novel targeted therapies. 2013 , 18, 199-210		1
202	Drug-induced acute liver failure. 2013 , 17, 575-86, viii		153
201	Genetic characterization to improve interpretation and clinical management of hepatotoxicity caused by tyrosine kinase inhibitors. 2013 , 14, 541-54		33
200	Role of the Adaptive Immune System in Idiosyncratic Drug-Induced Liver Injury. 2013 , 175-193		3
199	Clinical Manifestations and Management of Drug-Induced Liver Diseases. 2013 , 229-240		0

198	Assessment of emerging biomarkers of liver injury in human subjects. 2013 , 132, 276-83		97
197	[Liver parameters in intensive care medicine]. 2013 , 138, 636-42		9
196	A proposed modification to Hy's law and Edish criteria in oncology clinical trials using aggregated historical data. <i>Pharmacoepidemiology and Drug Safety</i> , 2013 , 22, 571-8	2.6	8
195	Idiosyncratic adverse drug reactions: current concepts. 2013 , 65, 779-808		212
194	Validity of diagnostic codes to identify cases of severe acute liver injury in the US Food and Drug Administration's Mini-Sentinel Distributed Database. <i>Pharmacoepidemiology and Drug Safety</i> , 2013 , 22, 861-72	2.6	45
193	Pre-Clinical Assessment of the Potential Intrinsic Hepatotoxicity of Candidate Drugs. 2013 ,		7
192	Drug Safety Evaluation Using a Healthcare Information Database: Using Statin-Related Adverse Drug Reactions as Examples. <i>Japanese Journal of Clinical Pharmacology and Therapeutics</i> , 2013 , 44, 193-200		1
191	Low-Level Alanine Aminotransferase Elevations in Osteoarthritis Patients within Approximately 2 Weeks of Treatment Initiation with Daily Acetaminophen: A Retrospective Analysis Evaluating Subsequent Alanine Aminotransferase Activity on Continued Acetaminophen Therapy. 2013 , 5, CMT.S11120		
190	Validation of acute liver injury cases in a population-based cohort study of oral antimicrobial users. 2014 , 9, 23-8		9
189	Causality assessment: Which is best-expert opinion or RUCAM?. 2014 , 4, 4-8		15
188	Pregnane X receptor and drug-induced liver injury. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2014 , 10, 1521-32	5.5	34
187	First-line crizotinib versus chemotherapy in ALK-positive lung cancer. <i>New England Journal of Medicine</i> , 2014 , 371, 2167-77	59.2	2116
186	Lost in Translation (LiT): IUPHAR Review 6. 2014 , 171, 2269-90		7
185	Mycobactericidal activity of sutezolid (PNU-100480) in sputum (EBA) and blood (WBA) of patients with pulmonary tuberculosis. <i>PLoS ONE</i> , 2014 , 9, e94462	3.7	96
184	Clinical features, diagnosis, and natural history of drug-induced liver injury. 2014 , 34, 134-44		48
183	DILI and drug development: a regulatory perspective. 2014 , 34, 215-26		20
182	Drug-induced liver injury and drug development: industry perspective. 2014 , 34, 227-39		66
181	Comprehensive assessment of the long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosis. 2014 , 19, 740-7		79

180	BG-12 (dimethyl fumarate): a review of mechanism of action, efficacy, and safety. 2014 , 30, 251-62		83
179	Non-steroidal anti-inflammatory drug use in chronic pain conditions with special emphasis on the elderly and patients with relevant comorbidities: management and mitigation of risks and adverse effects. 2014 , 70, 1159-72		102
178	Risk of acute liver injury associated with the use of moxifloxacin and other oral antimicrobials: a retrospective, population-based cohort study. 2014 , 34, 336-49		20
177	Drug-induced liver injury: morbidity, mortality, and Hy's law. 2014 , 147, 20-4		26
176	ACG Clinical Guideline: the diagnosis and management of idiosyncratic drug-induced liver injury. <i>American Journal of Gastroenterology</i> , 2014 , 109, 950-66; quiz 967	0.7	469
175	Efficacy and safety of maraviroc vs. efavirenz in treatment-naive patients with HIV-1: 5-year findings. 2014 , 28, 717-25		32
174	Leberfunktionsstörungen in der Intensivmedizin. 2015 , 18, 174-181		
173	Incidence of liver injury among cancer patients receiving chemotherapy in an integrated health system. <i>Pharmacoepidemiology and Drug Safety</i> , 2015 , 24, 427-34	2.6	10
172	Prevalence and incidence of liver dysfunction and assessment of biomarkers of liver disease in HIV-infected Asian children. 2015 , 34, e153-8		9
171	Treatment of PD-1(-/-) mice with amodiaquine and anti-CTLA4 leads to liver injury similar to idiosyncratic liver injury in patients. <i>Hepatology</i> , 2015 , 61, 1332-42	11.2	98
170	Association study of UGT1A9 promoter polymorphisms with DILI based on systematically regional variation screen in Chinese population. 2015 , 15, 326-31		7
169	Safety of biologic and nonbiologic disease-modifying antirheumatic drug therapy in veterans with rheumatoid arthritis and hepatitis B virus infection: a retrospective cohort study. 2015 , 17, 136		11
168	Mitigation of Methimazole-Induced Hepatic Injury by Taurine in Mice. 2015 , 83, 143-58		23
167	Causes, clinical features and outcomes of drug-induced liver injury in hospitalized patients in a Chinese tertiary care hospital. 2015 , 4, 802		23
166	Diagnostic and predictive performance and standardized threshold of traditional biomarkers for drug-induced liver injury in rats. 2015 , 35, 165-72		7
165	Drug-Induced Liver Injury Is a Major Risk for New Drugs. 2015 , 33, 458-63		9
164	The Art and Science of Diagnosing and Managing Drug-induced Liver Injury in 2015 and Beyond. 2015 , 13, 2173-89.e8		51
163	Risk of Acute Liver Failure in Patients With Drug-Induced Liver Injury: Evaluation of Hy's Law and a New Prognostic Model. 2015 , 13, 2360-8		43

162	Drug-induced liver injury: the dawn of biomarkers?. 2015 , 7, 34		34
161	Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple Sclerosis. <i>New England Journal of Medicine</i> , 2015 , 373, 1418-28	59.2	203
160	Semaglutide, a once-weekly human GLP-1 analog, does not reduce the bioavailability of the combined oral contraceptive, ethinylestradiol/levonorgestrel. 2015 , 55, 497-504		85
159	[Liver dysfunctions in intensive care patients--consequences for the treatment of invasive Candida infections]. 2015 , 110, 138-44		1
158	Application of high-throughput sequencing to circulating microRNAs reveals novel biomarkers for drug-induced liver injury. 2015 , 143, 268-76		71
157	Therapeutic efficacy of monthly subcutaneous injection of daclizumab in relapsing multiple sclerosis. 2016 , 10, 119-38		7
156	Scientific and Regulatory Perspectives in Herbal and Dietary Supplement Associated Hepatotoxicity in the United States. 2016 , 17, 331		60
155	Blood transcript immune signatures distinguish a subset of people with elevated serum ALT from others given acetaminophen. 2016 , 99, 432-41		12
154	Can rechallenge be done safely after mild or moderate drug-induced liver injury?. <i>Hepatology</i> , 2016 , 63, 691-3	11.2	7
153	The Use of Genetically Modified Animals in Discovery Toxicology. 2016 , 298-313		1
152	Validity of diagnostic codes and laboratory measurements to identify patients with idiopathic acute liver injury in a hospital database. <i>Pharmacoepidemiology and Drug Safety</i> , 2016 , 25 Suppl 1, 21-8	2.6	11
151	Occurrence of hepatotoxicity with pazopanib and other anti-VEGF treatments for renal cell carcinoma: an observational study utilizing a distributed database network. 2016 , 78, 559-66		12
150	Drug-Induced Liver Injury in Patients With Preexisting Chronic Liver Disease in Drug Development: How to Identify and Manage?. 2016 , 151, 1046-1051		30
149	Safety and tolerability profile of daclizumab in patients with relapsing-remitting multiple sclerosis: An integrated analysis of clinical studies. 2016 , 9, 36-46		37
148	Current and future directions in the treatment and prevention of drug-induced liver injury: a systematic review. 2016 , 10, 517-36		57
147	Redox-Dependent HMGB1 Isoforms as Pivotal Co-Ordinators of Drug-Induced Liver Injury: Mechanistic Biomarkers and Therapeutic Targets. 2016 , 24, 652-65		20
146	Long-term (up to 4.5 years) treatment with fingolimod in multiple sclerosis: results from the extension of the randomised TRANSFORMS study. 2016 , 87, 468-75		109
145	Evaluation of miR-122 as a Serum Biomarker for Hepatotoxicity in Investigative Rat Toxicology Studies. 2016 , 53, 211-21		31

144	Features of Autoimmune Hepatitis in Patients With Drug-induced Liver Injury. 2017 , 15, 103-112.e2	100
143	Safety of Biologic and Nonbiologic Disease-modifying Antirheumatic Drug Therapy in Veterans with Rheumatoid Arthritis and Hepatitis C Virus Infection. 2017 , 44, 565-570	6
142	Refining Liver Safety Risk Assessment: Application of Mechanistic Modeling and Serum Biomarkers to Cimaglermin Alfa (GGF2) Clinical Trials. 2017 , 102, 961-969	27
141	Randomized trial of preladenant, given as monotherapy, in patients with early Parkinson disease. 2017 , 88, 2198-2206	41
140	Supernatant from Hepatocyte Cultures with Drugs That Cause Idiosyncratic Liver Injury Activates Macrophage Inflammasomes. 2017 , 30, 1327-1332	36
139	Transaminase Levels and Hepatic Events During Tocilizumab Treatment: Pooled Analysis of Long-Term Clinical Trial Safety Data in Rheumatoid Arthritis. 2017 , 69, 1751-1761	55
138	Evaluation of a human in vitro hepatocyte-NPC co-culture model for the prediction of idiosyncratic drug-induced liver injury: A pilot study. 2017 , 4, 89-103	16
137	The transformation in biomarker detection and management of drug-induced liver injury. <i>Liver International</i> , 2017 , 37, 1582-1590	7.9 54
136	Drug-induced liver injury in Oncology. 2017 , 28, 2013-2020	21
135	Monoclonal Antibodies for Relapsing Multiple Sclerosis: A Review of Recently Marketed and Late-Stage Agents. 2017 , 31, 357-371	10
134	Drug-Induced Liver Injury. 2017 , 389-403	1
133	Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial. 2017 , 390, 1949-1961	815
132	Idiosyncratic drug-induced liver injury: A short review. 2017 , 1, 494-500	17
131	Dietary supplementation with cysteine prevents adverse metabolic outcomes of repeated cures with paracetamol in old rats. 2017 , 118, 889-896	1
130	Acute Liver Failure Induced by Anti-infectious Drugs: Causes and Management. 2017 , 16, 276-285	5
129	The Causes and Clinical Spectrum of Drug-Induced Cholestatic Liver Injury. 2017 , 16, 130-136	
128	Drug-induced liver injury: Advances in mechanistic understanding that will inform risk management. 2017 , 101, 469-480	108
127	Long-term safety profile of tolvaptan in autosomal dominant polycystic kidney disease patients: TEMPO Extension Japan Trial. 2017 , 9, 93-104	12

126	Transient Changes in Hepatic Physiology That Alter Bilirubin and Bile Acid Transport May Explain Elevations in Liver Chemistries Observed in Clinical Trials of GGF2 (Cimaglermin Alfa). 2018 , 161, 401-411		13
125	Safety data and withdrawal of hepatotoxic drugs. 2021 , 76, 715-723		25
124	Pharmacokinetic drug evaluation of daclizumab for the treatment of relapsing-remitting multiple sclerosis. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2018 , 14, 341-352	5.5	1
123	Drug idiosyncrasy due to pirfenidone presenting as acute liver failure: Case report and mini-review of the literature. 2018 , 2, 142-147		18
122	Serious Liver Injury Associated with Macitentan: A Case Report. 2018 , 38, e22-e24		11
121	Acetaminophen as a Renoprotective Adjunctive Treatment in Patients With Severe and Moderately Severe Falciparum Malaria: A Randomized, Controlled, Open-Label Trial. <i>Clinical Infectious Diseases</i> , 2018 , 67, 991-999	11.6	28
120	How to construct an optimal interim report: What the data monitoring committee does and doesn't need to know. 2018 , 15, 359-365		11
119	Interpretation, Integration, and Implementation of In Vitro Assay Data: The Predictive Toxicity Challenge. 2018 , 345-364		2
118	Perspectives on the Regulatory and Clinical Science of Drug-Induced Liver Injury (DILI). 2018 , 367-393		3
117	In silico modeling to optimize interpretation of liver safety biomarkers in clinical trials. 2018 , 243, 300-307		17
116	Acute liver failure induced by idiosyncratic reaction to drugs: Challenges in diagnosis and therapy. <i>Liver International</i> , 2018 , 38, 6-14	7.9	38
115	Pre-Existing Liver Disease and Toxicity of Antifungals. 2018 , 4,		19
114	Idiosyncratic Drug-Induced Liver Injury: Mechanisms and Susceptibility Factors. 2018 , 625-650		
113	Nintedanib plus Sildenafil in Patients with Idiopathic Pulmonary Fibrosis. <i>New England Journal of Medicine</i> , 2018 , 379, 1722-1731	59.2	135
112	Ginseng-Related Drug-Induced Liver Injury. 2018 , 12, 439-446		8
111	Drug-induced liver injury: a safety review. 2018 , 17, 795-804		21
110	Trends in reporting drug-associated liver injuries in Taiwan: a focus on amiodarone. <i>International Journal of Clinical Pharmacy</i> , 2018 , 40, 911-920	2.3	4
109	Herb-Induced Liver Injuries in Developing Nations: An Update. 2018 , 6,		31

108	Idiosyncratic Adverse Drug Reactions. 2018 , 681-716		3
107	Laboratory Tests in Liver Disease. 2018 , 43-53		1
106	Long-term Pooled Safety Analysis of Palbociclib in Combination With Endocrine Therapy for HR+/HER2- Advanced Breast Cancer. 2019 , 111, 419-430		32
105	Comparison of Different Liver Test Thresholds for Drug-Induced Liver Injury: Updated RUCAM versus Other Methods. <i>Frontiers in Pharmacology</i> , 2019 , 10, 816	5.6	8
104	Drug-Induced Liver Injury - Types and Phenotypes. <i>New England Journal of Medicine</i> , 2019 , 381, 264-273	59.2	171
103	Results from a long-term open-label extension study of adjunctive buprenorphine/samidorphan combination in patients with major depressive disorder. 2019 , 44, 2268-2276		9
102	Long-term safety of certolizumab pegol in rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, psoriasis and Crohn's disease: a pooled analysis of 11 317 patients across clinical trials. 2019 , 5, e000942		26
101	Simvastatin Improves Neutrophil Function and Clinical Outcomes in Pneumonia. A Pilot Randomized Controlled Clinical Trial. 2019 , 200, 1282-1293		53
100	The Liver in Systemic Illness. 2019 , 361-396		0
99	Drug-induced liver injury. 2019 , 5, 58		148
98	Role of Liver Transplantation in Tolvaptan-Associated Acute Liver Failure. 2019 , 4, 1653-1657		6
97	Mechanisms of Hepatic Cholestatic Drug Injury. 2019 , 7, 86-92		16
96	Idiosyncratic drug-induced liver injury in patients: Detection, severity assessment, and regulatory implications. 2019 , 85, 165-193		8
95	EASL Clinical Practice Guidelines: Drug-induced liver injury. <i>Journal of Hepatology</i> , 2019 , 70, 1222-1261	13.4	327
94	Consensus: guidelines: best practices for detection, assessment and management of suspected acute drug-induced liver injury during clinical trials in patients with nonalcoholic steatohepatitis. 2019 , 49, 702-713		16
93	Effect of Ubrogepant vs Placebo on Pain and the Most Bothersome Associated Symptom in the Acute Treatment of Migraine: The ACHIEVE II Randomized Clinical Trial. 2019 , 322, 1887-1898		119
92	Ubrogepant for the Treatment of Migraine. <i>New England Journal of Medicine</i> , 2019 , 381, 2230-2241	59.2	138
91	Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome. 2019 , 33, 379-389		287

90	Final Results of the RHAPSODY Trial: A Multi-Center, Phase 2 Trial Using a Continual Reassessment Method to Determine the Safety and Tolerability of 3K3A-APC, A Recombinant Variant of Human Activated Protein C, in Combination with Tissue Plasminogen Activator, Mechanical Thrombectomy or both in Moderate to Severe Acute Ischemic Stroke. 2019 , 85, 125-136	63
89	Serum biomarkers of drug-induced liver injury: Current status and future directions. 2019 , 20, 2-10	13
88	Risk factors for acute liver failure among inpatients with anti-tuberculosis drug-induced liver injury. 2020 , 48, 30060518811512	6
87	Real-World Delivery of Rucaparib to Patients with Ovarian Cancer: Recommendations Based on an Integrated Safety Analysis of ARIEL2 and Study 10. 2020 , 25, e109-e119	7
86	Long-Term Safety Evaluation of Ubrogepant for the Acute Treatment of Migraine: Phase 3, Randomized, 52-Week Extension Trial. 2020 , 60, 141-152	40
85	Drug-Induced Liver Injury from Statins. 2020 , 24, 107-119	8
84	Consensus guidelines: best practices for detection, assessment and management of suspected acute drug-induced liver injury occurring during clinical trials in adults with chronic cholestatic liver disease. 2020 , 51, 90-109	10
83	Mathematical modelling and statistical analysis of indocyanine green and other biomarkers of hepatic function and drug-induced liver injury. 2020 , 16, 100134	
82	A Severe Case of Idiosyncratic Hepatotoxicity with Unfractionated Heparin. 2021 , 56, 777-785	1
81	A case of teriflunomide-induced hepatic injury: assessing causality using available rules. 2020 , 4, 62-66	1
80	Liver Injury Among Japanese Patients Treated Using Prophylactic Enoxaparin After Colorectal Surgery. 2021 , 66, 2805-2815	2
79	Machine-Learning Prediction of Oral Drug-Induced Liver Injury (DILI) via Multiple Features and Endpoints. 2020 , 2020, 4795140	4
78	The Origins of the Modern-Day Study of Drug Hepatotoxicity: Focus on Hyman J. Zimmerman. 2020 , 15, S25-S36	0
77	Drug Induced Liver Injury (DILI). Mechanisms and Medicinal Chemistry Avoidance/Mitigation Strategies. 2020 , 63, 11397-11419	20
76	A Randomized, Double-Blind, Placebo-Controlled Trial of Vilazodone in Children and Adolescents with Major Depressive Disorder with Twenty-Six-Week Open-Label Follow-Up. 2020 , 30, 355-365	2
75	Restriction of non-opioid analgesics sold over-the-counter in Denmark: A national study of impact on poisonings. 2020 , 268, 61-68	7
74	Understanding Idiosyncratic Toxicity: Lessons Learned from Drug-Induced Liver Injury. 2020 , 63, 6436-6461	18
73	NRF-2 and nonalcoholic fatty liver disease. 2020 , 19, 458-465	9

72	Signal Detection of Potentially Drug-Induced Liver Injury in Children Using Electronic Health Records. 2020 , 8, 171		1
71	The Indian Network of Drug-Induced Liver Injury: Etiology, Clinical Features, Outcome and Prognostic Markers in 1288 Patients. <i>Journal of Clinical and Experimental Hepatology</i> , 2021 , 11, 288-298	4.1	10
70	Efficacy and Safety of Tocilizumab for Polyarticular-Course Juvenile Idiopathic Arthritis in the Open-Label Two-Year Extension of a Phase III Trial. 2021 , 73, 530-541		8
69	HLA-B*35:01 and Green Tea-Induced Liver Injury. <i>Hepatology</i> , 2021 , 73, 2484-2493	11.2	8
68	Drug-Induced Liver Injury in Older Adults. 2021 , 1391-1406		
67	Drug-induced liver injury: Asia Pacific Association of Study of Liver consensus guidelines. <i>Hepatology International</i> , 2021 , 15, 258-282	8.8	15
66	Drug Induced Liver Injury in Geriatric Patients Detected by a Two-Hospital Prospective Pharmacovigilance Program: A Comprehensive Analysis Using the Roussel Uclaf Causality Assessment Method. <i>Frontiers in Pharmacology</i> , 2020 , 11, 600255	5.6	3
65	Drug induced liver injury: from pathogenesis to liver transplantation. <i>Minerva Gastroenterology</i> , 2021 , 67,	3	3
64	Outcomes and Predictors of Mortality in Patients With Drug-Induced Liver Injury at a Tertiary Hospital in South India: A Single-Centre Experience. <i>Journal of Clinical and Experimental Hepatology</i> , 2021 , 11, 163-170	4.1	2
63	What is the optimal antibiotic treatment strategy for carbapenem-resistant <i>Acinetobacter baumannii</i> (CRAB)? A multicentre study in Korea. <i>Journal of Global Antimicrobial Resistance</i> , 2021 , 24, 429-439	3.4	3
62	A partially randomised trial of pretomanid, moxifloxacin and pyrazinamide for pulmonary TB. <i>International Journal of Tuberculosis and Lung Disease</i> , 2021 , 25, 305-314	2.1	7
61	ACG Clinical Guideline: Diagnosis and Management of Idiosyncratic Drug-Induced Liver Injury. <i>American Journal of Gastroenterology</i> , 2021 , 116, 878-898	0.7	31
60	Modeling approaches for reducing safety-related attrition in drug discovery and development: a review on myelotoxicity, immunotoxicity, cardiovascular toxicity, and liver toxicity. <i>Expert Opinion on Drug Discovery</i> , 2021 , 16, 1365-1390	6.2	3
59	Drug-induced liver injury at a tertiary care centre in Germany: Model for end-stage liver disease is the best predictor of outcome. <i>Liver International</i> , 2021 , 41, 2383-2395	7.9	0
58	A phase 2 study of nilotinib in pediatric patients with CML: long-term update on growth retardation and safety. <i>Blood Advances</i> , 2021 , 5, 2925-2934	7.8	3
57	Atogepant for the Preventive Treatment of Migraine. <i>New England Journal of Medicine</i> , 2021 , 385, 695-706	9.2	29
56	Novel predictors for liver transplantation or death in drug-induced acute liver failure. <i>European Journal of Gastroenterology and Hepatology</i> , 2021 ,	2.2	0
55	Proof-of-concept study to evaluate the safety and efficacy of saroglitazar in patients with primary biliary cholangitis. <i>Journal of Hepatology</i> , 2021 ,	13.4	1

54	Predicting Drug-Induced Hepatotoxicity: In Vitro, In Silico and In Vivo Approaches. <i>Methods and Principles in Medicinal Chemistry</i> , 2009 , 345-385	0.4	3
53	Drug-Induced Liver Injury in Older Adults. 2020 , 1-16		1
52	A controlled human malaria infection model enabling evaluation of transmission-blocking interventions. <i>Journal of Clinical Investigation</i> , 2018 , 128, 1551-1562	15.9	59
51	Safety and Reproducibility of a Clinical Trial System Using Induced Blood Stage Plasmodium vivax Infection and Its Potential as a Model to Evaluate Malaria Transmission. <i>PLoS Neglected Tropical Diseases</i> , 2016 , 10, e0005139	4.8	29
50	Identification of metabolites, clinical chemistry markers and transcripts associated with hepatotoxicity. <i>PLoS ONE</i> , 2014 , 9, e97249	3.7	22
49	Propylthiouracil-Induced Liver Injury in Mice and the Protective Role of Taurine. <i>Pharmaceutical Sciences</i> , 2015 , 21, 94-101		9
48	Lapatinib promotes the incidence of hepatotoxicity by increasing chemotherapeutic agent accumulation in hepatocytes. <i>Oncotarget</i> , 2015 , 6, 17738-52	3.3	13
47	Current Challenges and Controversies in Drug-Induced Liver Injury. <i>Drug Safety</i> , 2012 , 35, 1099-1117	5.1	4
46	Drug-Induced Liver Injuries (Clinical Guidelines for Physicians). <i>Russian Journal of Gastroenterology Hepatology Coloproctology</i> , 2019 , 29, 101-131	1	22
45	Drug induced liver injury: East versus West - a systematic review and meta-analysis. <i>Clinical and Molecular Hepatology</i> , 2020 , 26, 142-154	6.9	8
44	Evaluation of Drug-Induced Liver Injury Developed During Hospitalization Using Electronic Health Record (EHR)-Based Algorithm. <i>Allergy, Asthma and Immunology Research</i> , 2020 , 12, 430-442	5.3	7
43	Liver injury induced by paracetamol and challenges associated with intentional and unintentional use. <i>World Journal of Hepatology</i> , 2020 , 12, 125-136	3.4	19
42	Assessing liver injury associated with antimycotics: Concise literature review and clues from data mining of the FAERS database. <i>World Journal of Hepatology</i> , 2014 , 6, 601-12	3.4	48
41	Drug-induced liver injury: Do we know everything?. <i>World Journal of Hepatology</i> , 2017 , 9, 491-502	3.4	47
40	The Dynamics of Liver Function Test Abnormalities after Malaria Infection: A Retrospective Observational Study. <i>American Journal of Tropical Medicine and Hygiene</i> , 2018 , 98, 1113-1119	3.2	28
39	Drug-Induced Liver Injury: Pattern Recognition and Future Directions. <i>Gut and Liver</i> , 2016 , 10, 27-36	4.8	34
38	Clinical management of Plasmodium knowlesi malaria. <i>Advances in Parasitology</i> , 2021 , 113, 45-76	3.2	1
37	The Role of Drug Metabolism in Toxicity. 1		

36	Bosutinib: a novel src/abl kinase inhibitor for chronic myelogenous leukemia. <i>Journal of the Advanced Practitioner in Oncology</i> , 2013 , 4, 451-5	0.7	5
35	Ombitasvir/Paritaprevir/Ritonavir, a New Regimen for Hepatitis C Virus Infection: Its Efficacy, Safety, and Drug-Drug Interaction. <i>Japanese Journal of Clinical Pharmacology and Therapeutics</i> , 2016 , 47, 155-171	0	1
34	Drug and herbal hepatotoxicity: an overview of clinical classifications. <i>Vnitřni Lekarství</i> , 2018 , 64, 384-393.	0.3	2
33	Laboratory Measurement of Hepatic Function. 2019 , 1398-1409		
32	Liver transplantation for azithromycin-induced severe liver injury. <i>Korean Journal of Transplantation</i> , 2020 , 34, 279-285	0.2	
31	Drug-Induced Liver Injury: Clinical and Etiologic Features at a Large Tertiary Teaching Hospital in China. <i>Medical Science Monitor</i> , 2020 , 26, e919435	3.2	1
30	Medikamentö-toxischer Leberschaden (DILI). <i>Pathologie</i> , 2020 , 117-157	0	
29	Biomarkers of idiosyncratic drug-induced liver injury (DILI) - a systematic review. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2021 , 17, 1327-1343	5.5	1
28	Validation of Multivariate Outlier Detection Analyses Used to Identify Potential Drug-Induced Liver Injury in Clinical Trial Populations. <i>Drug Safety</i> , 2012 , 35, 865-875	5.1	1
27	Drug-induced liver injuries in practice of primary care physician (review of clinical recommendations). <i>Medical Alphabet</i> , 2020 , 58-69	0.3	1
26	Novel circulating- and imaging-based biomarkers to enhance the mechanistic understanding of human drug-induced liver injury. <i>Journal of Clinical and Translational Research</i> , 2017 , 3, 199-211	1.1	2
25	Evaluation of the Pharmacokinetic Interaction and Safety of Ubrogepant Coadministered With Esomeprazole Magnesium. <i>Clinical Pharmacology in Drug Development</i> , 2021 ,	2.3	1
24	Exploring Indicators of Hepatotoxicity-Related Post-Marketing Regulatory Actions: A Retrospective Analysis of Drug Approval Data. <i>The Saudi Journal of Health Systems Research</i> , 1-5		
23	RegiSCAR DRESS (Drug Reaction with Eosinophilia and Systemic Symptoms) Validation Scoring System and Japanese Consensus Group Criteria for Atypical Drug-Induced Hypersensitivity Syndrome (DiHS): A Comparative Analysis.. <i>Indian Dermatology Online Journal</i> , 2022 , 13, 40-45	0.9	0
22	Safety of Fingolimod in Patients with Multiple Sclerosis Switched from Natalizumab: Results from TRANSITION-A 2-Year, Multicenter, Observational, Cohort Study.. <i>Brain Sciences</i> , 2022 , 12,	3.4	0
21	The effect of regularly dosed acetaminophen versus no acetaminophen on renal function in Plasmodium knowlesi malaria (PACKNOW): a randomised controlled trial.. <i>Clinical Infectious Diseases</i> , 2022 ,	11.6	0
20	Real world considerations for newly approved CGRP receptor antagonists in migraine care.. <i>Expert Review of Neurotherapeutics</i> , 2022 ,	4.3	2
19	Data_Sheet_1.docx. 2020 ,		

18	Associated factors and safety of the rapidly achieving first therapeutic target of warfarin in hospitalized patients: a retrospective cohort study.. <i>International Journal of Clinical Pharmacy</i> , 2022 , 1	2.3	0
17	Gepants ̄a long way to cure: a narrative review. <i>Neurological Sciences</i> ,	3.5	0
16	Drug-Associated Liver Injury Related to Antipsychotics. <i>Journal of Clinical Psychopharmacology</i> , Publish Ahead of Print,	1.7	0
15	Clinical Significance of Transient Asymptomatic Elevations in Aminotransferase (TAEAT) in Oncology. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , Publish Ahead of Print,	2.7	1
14	Alanine Aminotransferase and Bilirubin Dynamic Evolution Pattern as a Novel Model for the Prediction of Acute Liver Failure in Drug-Induced Liver Injury. <i>Frontiers in Pharmacology</i> , 13,	5.6	
13	Acute hepatitis following mRNA BNT162b2 COVID-19 vaccination.		
12	AASLD practice guidance on drug, herbal, and dietary supplement-induced liver injury.		1
11	Clinical assessment of suspected drug-induced liver injury and its management.		0
10	The Role of Drug Metabolism in Toxicity. 2022 , 605-676		0
9	Gepants for Acute and Preventive Migraine Treatment: A Narrative Review. 2022 , 12, 1612		0
8	Green Tea Consumption Is Increasing but There Are Significant Hepatic Side Effects. 2022 , 2022, 1-5		0
7	Assessment of the Frequency, Phenotypes, and Outcomes of Acute Liver Injury Associated with Amoxicillin/Clavulanate in 1.4 Million Patients in the Veterans Health Administration.		0
6	Phase Ib, open-label, fixed-sequence, drug-drug interaction, safety, and tolerability study between atogepant and ubrogepant in participants with a history of migraine.		1
5	Long-term efficacy and safety of inclisiran in patients with high cardiovascular risk and elevated LDL cholesterol (ORION-3): results from the 4-year open-label extension of the ORION-1 trial. 2023 ,		4
4	Drug-induced liver injury caused by conventional drugs, using cases based on the Roussel Uclaf causality assessment method. 2023 , 385-407		0
3	Overview of Side-Effects of Antibacterial Fluoroquinolones: New Drugs versus Old Drugs, a Step Forward in the Safety Profile?. 2023 , 15, 804		1
2	Challenges and opportunities in NASH drug development. 2023 , 29, 562-573		0
1	A retrospective study to evaluate Hyβ Law, DrILTox ALF score, Robles-Diaz model, and a new logistic regression model for predicting acute liver failure in Chinese patients with drug-induced liver injury. 1-5		0

